Literature DB >> 23993879

Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.

Grazyna Bochenek1, Joanna Kuschill-Dziurda2, Krystyna Szafraniec3, Hanna Plutecka2, Andrzej Szczeklik2, Ewa Nizankowska-Mogilnicka2.   

Abstract

BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is recognized as a distinct asthma phenotype. It usually has a severe course accompanied by chronic hyperplastic eosinophilic sinusitis with nasal polyps, blood eosinophilia, and increased concentrations of urinary leukotriene E4 (LTE4). More insightful analysis of individual patients shows this group to be nonhomogeneous.
OBJECTIVE: We sought to identify any likely subphenotypes in a cohort of patients with AERD through the application of latent class analysis (LCA).
METHODS: Clinical data from 201 patients with AERD (134 women) were collected from questionnaires. Standard spirometry, atopy traits, blood eosinophilia, and urinary LTE4 concentrations were evaluated. LCA was applied to identify possible AERD subphenotypes.
RESULTS: Four classes (subphenotypes) within the AERD phenotype were identified as follows: class 1, asthma with a moderate course, intensive upper airway symptoms, and blood eosinophilia (18.9% of patients); class 2, asthma with a mild course, relatively well controlled, and with low health care use (34.8% of patients); class 3, asthma with a severe course, poorly controlled, and with severe exacerbations and airway obstruction (41.3% of patients); and class 4, poorly controlled asthma with frequent and severe exacerbations in female subjects (5.0% of patients). Atopic status did not affect class membership. Patients with particularly intensive upper airway symptoms had the highest levels of blood eosinophilia and the highest concentrations of urinary LTE4.
CONCLUSIONS: LCA revealed unique AERD subphenotypes, thus corroborating the heterogeneity of this population. Such discrimination might facilitate more individualized treatment in difficult-to-treat patients.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  AERD; Aspirin; Aspirin-exacerbated respiratory disease; Cysteinyl leukotriene; ED; Emergency department; ICU; Intensive care unit; LCA; LTE(4); Latent class analysis; Leukotriene E(4); NAEPP EPR3; NSAID; National Asthma Education and Prevention Program Expert Panel Report 3; Nonsteroidal anti-inflammatory drug; TENOR; The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens; aspirin-exacerbated respiratory disease; asthma phenotype; cysLT; latent class analysis; nonsteroidal anti-inflammatory drugs

Mesh:

Substances:

Year:  2013        PMID: 23993879     DOI: 10.1016/j.jaci.2013.07.004

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  26 in total

Review 1.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

2.  Comment on: "Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives".

Authors:  İnsu Yılmaz; Murat Türk
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

3.  Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.

Authors:  Whitney W Stevens; Anju T Peters; Annemarie G Hirsch; Cara M Nordberg; Brian S Schwartz; Dione G Mercer; Mahboobeh Mahdavinia; Leslie C Grammer; Kathryn E Hulse; Robert C Kern; Pedro Avila; Robert P Schleimer
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-09

Review 4.  Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.

Authors:  Whitney W Stevens; Robert P Schleimer
Journal:  Immunol Allergy Clin North Am       Date:  2016-09-13       Impact factor: 3.479

5.  Automated identification of an aspirin-exacerbated respiratory disease cohort.

Authors:  Katherine N Cahill; Christina B Johns; Jing Cui; Paige Wickner; David W Bates; Tanya M Laidlaw; Patrick E Beeler
Journal:  J Allergy Clin Immunol       Date:  2016-07-25       Impact factor: 10.793

6.  Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.

Authors:  Katherine N Cahill; Benjamin A Raby; Xiaobo Zhou; Feng Guo; Derek Thibault; Andreas Baccarelli; Hyang-Min Byun; Neil Bhattacharyya; John W Steinke; Joshua A Boyce; Tanya M Laidlaw
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

7.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

Review 8.  Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function.

Authors:  Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2019-10       Impact factor: 10.793

9.  Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.

Authors:  William C Scott; Katherine N Cahill; Ginger L Milne; Ping Li; Quanhu Sheng; Li Ching Huang; Spencer Dennis; Jacob Snyder; Ashley M Bauer; Rakesh K Chandra; Naweed I Chowdhury; Justin H Turner
Journal:  J Allergy Clin Immunol       Date:  2020-11-12       Impact factor: 10.793

Review 10.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.